Main Content
About COPD
Chronic obstructive pulmonary disease (COPD) compromises some 65 million people. It claimed 3.2 million lives in 2015, making it the third cause of death worldwide. Thus, it constitutes an enormous socio-economic burden, which is predicted to increase by 30 % within 10 years due to aging populations. Annual excess socio-economical costs for treatment, loss of working force, and quality of life are estimated up to 37,000 € per patient in Germany and more than 48 billion € in total in the EU.
About us
We are a multidisciplinary team of clinicians, experimentalists, computer scientists, patient representatives, and a medium-sized company. We will implement a Personalized Medicine platform for COPD treatment – PerMed-COPD – to translate recent research results into improved diagnosis and classification of COPD in clinical practice and into the development of effective personalized medical treatments. We are generously supported by the German Federal Ministry of Education and Research (Bundesministerium für Bildung und Forschung; BMBF). The DLR serves as PerMed-COPD’s project execution organization.
